Articles

Tim's story explains the risks of buying SARMs online.

Learn how we manage complaints about therapeutic goods advertising.

Indications proposed by industry during the 2017 public comment period have been published

Invitation to comment on discussion paper now published

Australian launch of a new product called Nyxoid nasal spray for opioid overdoses

This update implements feedback from stakeholders to make the database more user-friendly

The SPF has been redrafted as two documents - a policy document, the SPF, and a guidance document, the Scheduling Handbook.

On 14 December 2018, the TGA issued an infringement notice for export of unlawful medicines from Australia

For some people, vitamins are an important part of their health.  Learn how the TGA regulates vitamins.

If screening and vaccination for HPV continue, Australia could be the first country in the world to eliminate cervical cancer.

Direction Notice issued to cease advertisement of prescription and illegal products

Find out how mandatory reporting of medicine shortages will help you.

The TGA is alerting consumers to the potential risks of purchasing electronic cigarette liquid

Dealing counterfeit and unapproved medicines is a serious offence as shown in recent TGA prosecution outcome in South Australia

Is there a hangover cure? Essential reading for anyone visited by spirits these holidays.

Infliximab and mycosis fungoides, infliximab and lupus-like syndrome, and medicine shortages mandatory reporting

This legal action follows an investigation by the Therapeutic Goods Administration

TGO 100 has been registered on the Federal Register of Legislation. It commences on 8 December 2018, repealing and replacing TGO 98

There will not be a decision announced on scheduling of alkyl nitrites on 29 November 2018. Further public consultation will be undertaken.

Reforms relating to accessing unapproved products include modifications to the Special Access Scheme and Authorised Prescriber scheme to allow streamlined access to certain unapproved therapeutic products.

The complementary medicine regulatory reforms include changes that will create a new approval pathway for listed complementary medicines and increase availability of information to support consumer decisions.

The prescription medicines regulatory reforms include changes that will bring medicines to market sooner in Australia, while maintaining a robust framework for safety, quality and efficacy.

Reforms to TGA advisory committees include changes that provide greater efficiencies and a reduction in the number of statutory advisory committees that provide independent advice to the TGA.

Standards minimise risk of misconnections; eltrombopag interference with test results; amniotic fluid tests

Cabozantinib (CABOMETYX) is the first medicine to be registered via the new COR-A pathway